BioNTech breaks into ADCs, gains HER2-targeting product in deal with DualityBio

For its entry into the ADC arena, BioNTech has obtained most global rights to a clinical, HER2-targeting product and a second program from Shanghai-based DualityBio for $170 million up front.

The initial payment builds on the $120 million in venture funding Duality Biologics Ltd. has announced since its 2020 establishment, giving the biotech additional runway for its ambitions around a pipeline that includes at least seven programs it has named thus far...